O8.06 ATRX AND TERT EXPRESSION IN RELAPSING LOW GRADE GLIOMA

著者: Calatozzolo, C., Patanè, M., Mazzetti, S., Eoli, M., Farinotti, M., Nunziata, R., Finocchiaro, G., Pollo, B.
出版事項 2014

OS2.3 Relevance of Neurofibromatosistype 1 and schwannomotosis in extramedullary spine tumors

著者: Eoli, M E, Bianchessi, D, Moscatelli, M, Chiapparini, L, Ibba, C, Finocchiaro, G, Bruzzone, M
出版年 Neuro Oncol (2019)

P02.01 MRI ASSESSMENT OF TUMOR SIZE IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL IMMUNOTHERAPY

著者: Cuccarini, V., Schettino, C., Acquino, D., Scotti, A., Cuppini, L., Finocchiaro, G., Bruzzone, M., Eoli, M.
出版事項 2014

P14.01 INTEGRATED GENETIC STUDIES OF NEUROFIBROMATOSIS TYPE 1. A TEN YEAR, ITALIAN EXPERIENCE

著者: Bianchessi, D., Morosini, S., Ibba, C., Esposito, S., Saletti, V., Riva, D., Natacci, F., Finocchiaro, G., Eoli, M.
出版事項 2014

P14.74 Remarkable response to Combined BRAF and MEK Inhibitors in two Adults with leptomeningeal carcinomatosis secondary to Pleomorphic Xantoastrocytoma grade II with BRAFv600E mu...

著者: Eoli, M, Pollo, B, Silvani, A, Paterra, R, Erbetta, A, Anghileri, E, Gaviani, P, Finocchiaro, G
出版年 Neuro Oncol (2019)

Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.

著者: Milanese, C, Salmaggi, A, La Mantia, L, Campi, A, Eoli, M, Savoiardo, M, Bianchi, G, Nespolo, A
出版事項 1990

P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses

著者: Pellegatta, S, Eoli, M, Bruzzone, MG, Cuzzubbo, S, Anghileri, E, Antozzi, C, Frigerio, S, Pollo, B, Parati, EA, Finocchiaro, G
出版事項 2014

OS2.8 Survival gain and immune response in glioblastoma patients treated with dendritic cell immunotherapy before and during adjuvant temozolomide

著者: Pellegatta, S., Eoli, M., Anghileri, E., Frigerio, S., Cuccarini, V., Antozzi, C., Pollo, B., Pessina, S., Bruzzone, M., Finocchiaro, G.
出版年 Neuro Oncol (2016)

P01.150 hypermutations in glioblastoma are associated with increased response to immunotherapy

著者: Anghileri, E, Zhao, J, Eoli, M, Langella, T, Pollo, B, Indraccolo, S, Pellegatta, S, Iavarone, A, Rabadan, R, Finocchiaro, G
出版年 Neuro Oncol (2018)

P02.03 INCREASED COUNTS OF NK AND NKT CELLS ARE ASSOCIATED WITH PROLONGED SURVIVAL IN PRIMARY GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL IMMUNOTHERAPY IN COMBINATION WITH RA...

著者: Pellegatta, S., Eoli, M., Cantini, G., Anghileri, E., Antozzi, C., Frigerio, S., Bruzzone, M., Pollo, B., Parati, E., Finocchiaro, G.
出版事項 2014

P14.64 Primary Central Nervous System Lymphoma (PCNSL) with HD- MTX based chemotherapy: tolerability and results

著者: Silvani, A, Anghileri, E, Simonetti, G, Eoli, M, Finocchiaro, G, Pollo, B, Farinotti, M, Fariselli, L, Gaviani, P
出版年 Neuro Oncol (2019)

O5.05 FLUORESCEIN-GUIDED REMOVAL OF HIGH-GRADE GLIOMAS WITH A DEDICATED FILTER ON THE SURGICAL MICROSCOPE: PRELIMINARY RESULTS OF THE FLUOGLIO STUDY

著者: Acerbi, F., Broggi, M., Cavallo, C., Anghileri, E., Eoli, M., Schiariti, M., Corte, E. La, Pollo, B., Boffano, C., Ferroli, P.
出版事項 2014

P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomus...

著者: van den Bent, M, French, P, Eoli, M, Sepulvado, J, Walenkamp, A, Weller, M, Looman, J, Ansell, P, Gorlia, T, Golfinopoulos, V
出版年 Neuro Oncol (2018)

P03.04 Observational, prospective study on complications and tolerability of PICC (central venous catheter with peripheral insertion) in neurooncological patients

著者: Simonetti, G, Sommariva, A, Basso Ricci, C, Anghileri, E, Botturi, A, Eoli, M, Gaviani, P, Lamperti, E, Moreschi, C, Silvani, A
出版年 Neuro Oncol (2018)

O3.03 THE SPECTRUM OF LATE PAROXYSMAL NEUROLOGICAL SYNDROMES AFTER BRAIN IRRADIATION

著者: Berzero, G., Group, Pavia Neuro-oncology, Ducray, F., Giometto, B., Silvani, A., Salmaggi, A., Eoli, M., Finocchiaro, G., Vidiri, A., Pace, A.
出版事項 2014

P05.02 A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically modified for human interferon-...

著者: Gentner, B, Ciceri, F, DiMeco, F, Legnani, F, Eoli, M, Pollo, B, Farina, F, Mazzoleni, S, Russo, C, Naldini, L, Finocchiaro, G
出版年 Neuro Oncol (2019)

P01.040 Identification of a predictive biomarker of response to regorafenib in relapsed glioblastoma patients <REGOMA trial>

著者: Lombardi, G, Indraccolo, S, de Salvo, G, Verza, M, Magni, G, Eoli, M, Rudà, R, Franceschi, E, Faedi, M, Lolli, I, Rizzato, S, Caccese, M, Gardiman, M, Zagonel, V
出版年 Neuro Oncol (2018)

OS7.3 Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

著者: Lombardi, G, Del Bianco, P, Brandes, A, Eoli, M, Rudà, R, Ibrahim, T, Lolli, I, Pace, A, Daniele, B, Pasqualetti, F, Rizzato, S, Bergo, E, Caccese, M, Padovan, M, Soffietti, R, De Salvo, G, Zagonel, V
出版年 Neuro Oncol (2019)

P11.08 Defining EGFR amplification status for clinical trial inclusion

著者: French, P, Eoli, M, Sepulveda, J, de Heer, I, Kros, J M, Walenkamp, A, Frenel, J, Franceschi, E, Clement, P, Weller, M, Ansell, P, Looman, J, Bain, E, Morfouace, M, Gorlia, T, van den Bent, M
出版年 Neuro Oncol (2019)

OS2.3 Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma <GBM> patients <PTS>

著者: Lombardi, G, de Salvo, G, Rudà, R, Franceschi, E, Eoli, M, Faedi, M, Pace, A, Lolli, I, Rizzato, S, Germano, D, Pasqualetti, F, Farina, M, Magni, G, Bellu, L, Caccese, M, Pambuku, A, Bergo, E, Indraccolo, S, Gardiman, M, Soffietti, R, Zagonel, V
出版年 Neuro Oncol (2018)